The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

As I reflect on how we can more effectively bring treatments to patients, one central question emerges: How can we transform scientific discoveries into better treatments? The intersection of science ...

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

"The future is already here—it's just not evenly distributed," Maulik Mukeshbhai Patel, a seasoned biopharmaceutical expert, remarked at a recent industry conference. His statement captures the ...

The partnership between Nvidia and Eli Lilly is not just about financial investment; it represents a new blueprint for how drugs will be developed in the future. By combining their resources and ...

Alex Zhavoronkov believes we’re cusp of what he calls “pharmaceutical superintelligence.” Courtesy of Insilico Medicine Zhavoronkov believes the industry is on the cusp of what he calls ...

Forbes contributors publish independent expert analyses and insights. Kathleen Walch covers AI, ML, and big data best practices. The pharmaceutical industry, known for its rigorous research, complex ...

Lisata Therapeutics and GATC Health Corp have initiated a strategic partnership that aims to enhance the drug discovery and development process using GATC's advanced AI-powered Multiomics Advanced ...

Government regulations affect drug development, often prolonging the process, but they ensure safety and efficacy to protect ...